Stay updated with breaking news from Nasdaq Alt. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Altimmune, Inc. (NASDAQ:ALT – Get Rating) has been assigned a consensus rating of “Moderate Buy” from the eight brokerages that are covering the firm, Marketbeat reports. One research analyst has rated the stock with a hold rating and seven have issued a buy rating on the company. The average 12 month target price among brokerages […]
JMP Securities reiterated their market outperform rating on shares of Altimmune (NASDAQ:ALT – Get Rating) in a report released on Friday, Benzinga reports. They currently have a $15.00 target price on the stock. Several other research analysts have also weighed in on the stock. Evercore ISI upped their price objective on shares of Altimmune from […]
Altimmune, Inc. (NASDAQ:ALT – Get Rating) Director David Drutz purchased 9,000 shares of the firm’s stock in a transaction that occurred on Thursday, March 23rd. The shares were bought at an average cost of $4.27 per share, for a total transaction of $38,430.00. Following the completion of the acquisition, the director now directly owns 29,484 […]
Shares of Altimmune, Inc. (NASDAQ:ALT – Get Rating) have earned an average rating of “Moderate Buy” from the eight research firms that are currently covering the firm, Marketbeat Ratings reports. One equities research analyst has rated the stock with a hold recommendation and seven have given a buy recommendation to the company. The average 1 […]
JMP Securities reissued their market outperform rating on shares of Altimmune (NASDAQ:ALT – Get Rating) in a report published on Wednesday morning, Benzinga reports. JMP Securities currently has a $26.00 target price on the stock. Other analysts also recently issued reports about the stock. Evercore ISI lifted their price objective on shares of Altimmune from […]